A therapy developed by Amsterdam’s Antoni van Leeuwenhoek Hospital for metastatic skin cancer should not enter the market, according to the European Medicines Agency. The agency said the clinical trials did not meet requirements and left uncertainty about whether the medicine was effective and safe.

The therapy’s future remains uncertain following the rejection.